Cogent Biosciences, Inc. (COGT)
27.44
-1.12
(-3.92%)
USD |
NASDAQ |
Nov 16, 16:00
27.78
+0.34
(+1.24%)
After-Hours: 20:00
Cogent Biosciences Enterprise Value : 4.293B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 4.293B |
| November 13, 2026 | 4.488B |
| November 12, 2026 | 4.589B |
| November 11, 2026 | 4.634B |
| November 10, 2026 | 5.024B |
| November 09, 2026 | 5.355B |
| November 06, 2026 | 5.025B |
| November 05, 2026 | 4.666B |
| November 04, 2026 | 4.998B |
| November 03, 2026 | 4.923B |
| November 02, 2026 | 4.692B |
| October 30, 2026 | 4.916B |
| October 29, 2026 | 5.080B |
| October 28, 2026 | 5.127B |
| October 27, 2026 | 5.088B |
| October 26, 2026 | 4.897B |
| October 23, 2026 | 4.949B |
| October 22, 2026 | 4.967B |
| October 21, 2026 | 4.988B |
| October 20, 2026 | 4.954B |
| October 19, 2026 | 4.740B |
| October 16, 2026 | 4.655B |
| October 15, 2026 | 4.653B |
| October 14, 2026 | 4.417B |
| October 13, 2026 | 4.406B |
| Date | Value |
|---|---|
| October 12, 2026 | 4.700B |
| October 09, 2026 | 4.913B |
| October 08, 2026 | 4.753B |
| October 07, 2026 | 4.763B |
| October 06, 2026 | 4.805B |
| October 05, 2026 | 4.890B |
| October 02, 2026 | 4.916B |
| October 01, 2026 | 5.015B |
| September 30, 2026 | 5.090B |
| September 29, 2026 | 4.951B |
| September 28, 2026 | 4.985B |
| September 25, 2026 | 5.062B |
| September 24, 2026 | 4.911B |
| September 23, 2026 | 4.908B |
| September 22, 2026 | 5.117B |
| September 21, 2026 | 5.009B |
| September 18, 2026 | 4.923B |
| September 17, 2026 | 5.214B |
| September 16, 2026 | 5.102B |
| September 15, 2026 | 5.136B |
| September 14, 2026 | 5.251B |
| September 11, 2026 | 5.251B |
| September 10, 2026 | 5.366B |
| September 09, 2026 | 5.383B |
| September 08, 2026 | 5.572B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 86.03B |
| Oncolytics Biotech, Inc. | 42.92M |
| Sangamo Therapeutics, Inc. | 36.86M |
| Sarepta Therapeutics, Inc. | 1.797B |
| Anixa Biosciences, Inc. | 73.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.43M |
| Total Expenses (Quarterly) | 111.43M |
| EPS Diluted (Quarterly) | -0.6434 |
| Earnings Yield | -9.11% |
| Normalized Earnings Yield | -8.988 |